Biology Reference
In-Depth Information
28. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops.
Oncogene
2005;
:2899-908.
29. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network.
Nature
2000;
24
408
:307-10.
30. Fridman JS, Lowe SW. Control of apoptosis by p53.
Oncogene
2003;
:9030-40.
31. Vousden KH, Lu X. Live or let die: the cell's response to p53.
Nat Rev Cancer
2002;
22
:594-604.
32. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation.
EMBO Rep
2003;
2
:671-7.
33. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, et al. SCFbeta-TRCP links Chk1
signaling to degradation of the Cdc25A protein phosphatase.
Genes Dev
2003;
4
:3062-74.
34. Sorensen CS, Syljuasen RG, Falck J, Schroeder T, Ronnstrand L, Khanna KK, et al. Chk1
regulates the S phase checkpoint by coupling the physiological turnover and ionizing
radiation-induced accelerated proteolysis of Cdc25A.
Cancer Cell
2003;
17
:247-58.
35. Zeng Y, Piwnica-Worms H. DNA damage and replication checkpoints in fission yeast require
nuclear exclusion of the Cdc25 phosphatase via 14-3-3 binding.
Mol Cell Biol
1999;
3
:7410-9.
36. Gardino AK, Yaffe MB. 14-3-3 proteins as signaling integration points for cell cycle control
and apoptosis.
Semin Cell Dev Biol
2011;
19
:688-95.
37. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for
targeted cancer therapy.
Cell Cycle
2009;
22
:3112-9.
38. Dobzhansky T. Genetics of Natural Populations. Xiii. Recombination and Variability in
Populations of Drosophila Pseudoobscura.
Genetics
1946;
8
:269-90.
39. Hartman JL, Garvik B, Hartwell L. Principles for the buffering of genetic variation.
Science
2001;
31
:1001-4.
40. Kaelin Jr. WG. The concept of synthetic lethality in the context of anticancer therapy.
Nat Rev
Cancer
2005;
291
:689-98.
41. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches
into the discovery of anticancer drugs.
Science
1997;
5
:1064-8.
42. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, et al. Kinase requirements
in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot
synthetic lethal screen.
Proc Natl Acad Sci U S A
2008;
278
:16484-9.
43. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of
BRCA2-deficient
105
tumours with inhibitors of poly(ADP-ribose) polymerase.
Nature
:913-7.
44. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the
DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Nature
2005;
2005;
434
434
:917-21.
45. Hoeijmakers
JH. Genome maintenance mechanisms
for preventing cancer.
Nature
:366-74.
46. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer.
Curr Opin Genet Dev
2008;
2001;
411
:80-6.
47. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-
ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med
2009;
18
:123-34.
48. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral
poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations
and recurrent ovarian cancer: a proof-of-concept trial.
Lancet
2010;
361
:245-51.
49. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-
ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer
correlating with platinum-free interval.
J Clin Oncol
2010;
376
:2512-9.
50. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-
ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
advanced breast cancer: a proof-of-concept trial.
Lancet
2010;
28
:235-44.
376
